Company / Operating Income
Arrowhead Pharmaceuticals Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$98.3M
FY2025
5-year range
-$601.1M / $98.3M
FY2021-FY2025
Trend
+116.4%
vs FY2024
Sector context
#40 of 204
Health Care
What the data says
Arrowhead Pharmaceuticals's operating income of $98M is higher than 80% of companies in the Health Care sector (FY2025). Operating Income returned to growth in FY2025 after 2 years of decline, reaching $98M.
Based on SEC 10-K filings.
$98M in FY2025. Top quartile in the Health Care sector.
Improved from -$149M to $98M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 204This company $98.3M Sector average $107.7M
▼
-8.7% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 116.4% year-over-year.
- Ranks #40 out of 204 companies in the Health Care sector.
- Lowest operating income in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $98.3M | +116.4% |
| FY2024 | -$601.1M | -303.3% |
| FY2023 | -$149.0M | -60.0% |
| FY2022 | -$93.2M | +37.5% |
| FY2021 | -$149.0M | -60.0% |
| FY2020 | -$93.2M | -151.8% |
| FY2019 | -$37.0M | +54.7% |
| FY2018 | -$81.7M | +14.8% |
| FY2017 | -$96.0M | -17.4% |
| FY2016 | -$81.7M | -232.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026